Former Executive Chairman of the Board and Chairman of the Board · GeneDx Holdings Corp. (WGS)

Jason Ryan

A named executive officer of GeneDx in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$441,470

Salary $6,490Stock awards $338,480

FY2023: $992,464

3rd of 3 named executive officers at GeneDx by FY2024 total.

3 named officers on file for GeneDx, FY2024

Jason Ryan’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • WGS’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GeneDx’s whole pay program stands against its peers

  • GeneDx’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on WGS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jason Ryan’s full pay file as a PDF — free

More than this page: up to 10 years of Jason’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jason Ryan compensation by year

GeneDx Summary Compensation Table · all 3 fiscal years held
In US dollars, as GeneDx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$510,923$343,471$6,490
Bonus$108,000$0$0
Stock awards$1,658,374$628,754$338,480
Option awards$876,649$0$0
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$39,515$20,239$96,500
Total$3,193,461$992,464$441,470

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GeneDx Holdings Corp. DEF 14A filed April 30, 2025, accession 0001818331-25-000075, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GeneDx Holdings Corp. filed document, accession 0001818331-25-000075. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

$3.2M
$992K
$441K
FY22
FY23
FY24
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU12,924$993,339—

Per the Outstanding Equity Awards at Fiscal Year-End table in GeneDx Holdings Corp.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

12 Form 4 lines since the FY2024 proxy (filed April 30, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-18Exercise or conversion derivative—3,576$0.000
2026-06-18Exercise or conversion—3,576$0.0015,480
2025-08-27Sale—8,969$126.15123,569
2025-08-27Sale—5,443$127.44118,126
2025-08-27Sale—9,890$129.59104,784
2025-08-27Sale—1,500$130.01103,284
2025-08-27Sale—1,150$129.6511,904
2025-08-27Sale—8,818$125.07132,538

The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

GeneDx’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Katherine StuelandChief Executive Officer$4,421,800
Kevin FeeleyChief Financial Officer$1,349,600
Jason Ryan · this pageFormer Executive Chairman of the Board and Chairman of the Board$441,470

Board service

GeneDx board · FY2023–FY2025
Director compensation in US dollars, as GeneDx reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$94,278$230,402$0$0$324,679
FY2024$80,000$338,480$0$0$418,480
FY2023—————

Each year as the company reported it in GeneDx's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: GeneDx pays directors a $40,000 cash retainer and $200,000 in Options and RSUs. As stated in GeneDx's FY2023 proxy.

The full GeneDx compensation record

free company brief

This page is one person within GeneDx's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the GeneDx proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GeneDx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Ryan's compensation dossier · One-time report. No refunds.